Non-ULT treatment, n = 93 | Treatment with ULT, n = 65 | p | |
---|---|---|---|
Age, yrs, mean ± SD | 70.57 ± 12.41 | 66.92 ± 14.06 | 0.087* |
Male sex, n (%) | 66 (70.21) | 54 (84.38) | 0.064** |
Duration of followup, days, mean ± SD | 1066.35 ± 749.70 | 1027.56 ± 779.26 | 0.754* |
Baseline eGFR, ml/min/1.73 m2, mean ± SD | 44.94 ± 8.09 | 44.70 ± 9.03 | 0.859* |
Systolic BP, mmHg, mean ± SD | 138.16 ± 24.96 | 129.54 ± 17.75 | 0.019* |
Diastolic BP, mmHg, mean ± SD | 79.51 ± 17.00 | 80.51 ± 13.79 | 0.699* |
Associated disease, n (%) | |||
HTN | 86 (91.49) | 50 (78.13) | 0.032** |
CVD | 20 (21.28) | 20 (31.25) | 0.219** |
DM | 40 (42.55) | 20 (31.25) | 0.204** |
Dyslipidemia | 57 (60.64) | 43 (67.19) | 0.503** |
Baseline BMI, kg/m2, mean ± SD | 26.40 ± 15.91 | 27.78 ± 17.78 | 0.617* |
Concomitant medications, n (%) | |||
ACEi | 5 (5.32) | 7 (10.94) | 0.316** |
ARB | 44 (46.81) | 22 (34.38) | 0.164** |
Low dose aspirin | 45 (47.87) | 27 (42.19) | 0.588** |
Diuretics | 31 (32.98) | 21 (32.81) | 1** |
NSAID | 0 (0) | 11 (16.92) | < 0.001** |
SUA level, mg/dl, mean ± SD | 8.00 ± 1.16 | 9.05 ± 1.91 | < 0.001* |
Etiology of CKD, n (%) | |||
Hypertensive | 27 (28.72) | 21 (32.81) | |
Diabetic | 39 (41.49) | 17 (26.56) | |
Glomerulonephritis | 5 (5.32) | 5 (7.81) | 0.113** |
Others | 4 (4.26) | 9 (14.06) | |
Unknown | 19 (20.21) | 12 (18.75) | |
Gout, n (%) | 0 (0) | 42 (65.63) | < 0.001 |
*** Independent 2-sample t test.
↵** Chi-squared test. ULT: urate lowering therapy; eGFR: estimated glomerular filtration rate; BP: blood pressure; HTN: hypertension; CVD: cerebrovascular disease; DM: diabetes mellitus; BMI: body mass index; ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; NSAID: nonsteroidal antiinflammatory drug; CKD: chronic kidney disease; SUA: serum uric acid.